January 15, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3628
Attn: Jessica Dickerson
| Re: | Marker Therapeutics, Inc. (the “Company”) |
Registration Statement on Form S-3
File No. 333-284233
Request for Acceleration
Dear Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) respectfully requests that the Securities and Exchange Commission take appropriate action to cause the above referenced Registration Statement on Form S-3 (the “Registration Statement”) to be declared effective at 4:00 p.m., Eastern Time, on Friday, January 17, 2025, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Mark Catchur of Shumaker, Loop & Kendrick, LLP at (813) 227-2264. Thank you for your assistance in this matter.
| Very truly yours, | ||
| By: | /s/ Juan Vera | |
| Juan Vera | ||
| President and Chief Executive Officer | ||
cc: Mark A. Catchur, Shumaker, Loop & Kendrick, LLP